ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1404

Machine Learning Model to Accurately Identify Rheumatoid Arthritis Patients Using Raw Electronic Health Record Data
Abstract Number: 1405

In Contrast to Anti-CCP, Then MMP Degraded and Citrullinated Vimentin (VICM) Is Both a Diagnostic and Treatment Response Biomarker
Abstract Number: 1406

Integrative Multi-omic Phenotyping in Blood Identifies Molecular Signatures and Candidate Biomarkers of ACPA-negative Rheumatoid Arthritis
Abstract Number: 1407

Longitudinal Lipid Profile and NT-proBNP Changes from Pre-clinical to Established Rheumatoid Arthritis: A 12 Years Follow up Explorative Study
Abstract Number: 1408

In RA Patients Without Prevalent CVD, Incident CVD Is Only Associated with Traditional Risk Factors: A 20-year Follow up in the CARRÉ Cohort Study
Abstract Number: 1409

Impact of a Hybrid Medical Care Model in the Rheumatoid Arthritis Patient-Reported Outcomes: A Non-inferiority Crossover Randomized Study
Abstract Number: 1410

Subclinical Atherosclerosis Is Not Related with Acid Uric in Rheumatoid Arthritis: Study of 1005 Patients of a Single University Hospital
Abstract Number: 1411

Predictors of Achieving Clinical Remission in ACPA-positive RA-patients Treated with Abatacept and Methotrexate or Methotrexate Monotherapy
Abstract Number: 1412

Coronary Microvascular Dysfunction in Patients with Rheumatoid Arthritis and Diabetes Mellitus: A Cross-sectional Study with 13NH3 Myocardial PET/CT
Abstract Number: 1413

Early Muscle Involvement in Patients with Rheumatoid Arthritis: A Large-Scale Cross-Sectional Study
Abstract Number: 1414

2022 Revision of the ACR/EULAR Remission Criteria for Rheumatoid Arthritis
Abstract Number: 1415

Different Bioactive Lipid Profile Predicts Response to TNF or IL6 Inhibitors in Rheumatoid Arthritis: Result of the CorEvitas CERTAIN Comparative Effectiveness Study
Abstract Number: 1416

Bioactive Lipid Profiling Can Identify Dynamic Biomarkers in Response to Biologic Therapy Result of the CorEvitas CERTAIN Comparative Effectiveness Study
Abstract Number: 1417

Clinical and Demographic Characteristics of Patients with RF+/ACPA+ RA and First-Line TNF Inhibitor versus Abatacept Treatment Choice in Real-World Clinical Practice
Abstract Number: 1418

Change in Disease Activity and Occurrence of Adverse Events After Initiation of Etanercept in Pediatric Patients with Juvenile Psoriatic Arthritis in the CARRA Registry

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].